Zentalis Pharmaceuticals (ZNTL) Files DEF 14A for April 28 Meeting
Published on 4/28/2026

AI Summary
Zentalis Pharmaceuticals (ZNTL) has filed a DEF 14A with the SEC ahead of its shareholder meeting scheduled for April 28. The filing typically includes details about proposals and issues to be voted on by shareholders. This meeting can significantly influence corporate governance and strategic decisions within the company. The event is part of Zentalis’ ongoing efforts to engage its investors and align on future directives.
Related News

Regulation
Republic Bancorp Inc (RBCA) Announces DEF 14A Filing on June 18
Jun 19

Regulation
TEVA Form 144 Filed on June 18 for Regulatory Compliance
Jun 19

Markets
Nektar Therapeutics (NKTR) Form 4 Filed on June 18 with Details
Jun 18

Regulation
Dali (DALI) Chief Engineer Deferred Prosecution Over 2024 Bridge Collapse
Jun 18